科尔奇辛联合治疗增加了关节炎患者的治疗耐受性:系统性审查和元分析
Changwei Zhao1,2, Xiaogang Hao2, Wenjun Cai3
1Changchun University of Chinese Medicine, Changchun, China.
PloS one
|January 8, 2025
概括
对关节炎的结合胆固醇治疗改善了患者的整体评估和硬,而不会增加不良事件. 这种治疗改善了关节炎患者的生活质量,提供了潜在的更安全,更有效的选择.
科学领域:
- 类风湿病学 类风湿病学
- 临床药理学 临床药理学
背景情况:
- 关节炎显著影响患者的生活质量,需要提高药物疗效和减少治疗副作用.
- 目前关于关节炎治疗中结合胆固醇治疗的证据有限,突出显示需要进一步调查.
研究的目的:
- 系统地评估与常规关节炎治疗相比,结合性胆固醇治疗的疗效和安全性.
- 综合随机对照试验 (RCT) 的证据,以告知临床实践关于素组合治疗的信息.
主要方法:
- 在2024年9月4日之前,对英语数据库进行了全面的文献搜索.
- 包括11个符合条件的RCT,研究质量使用Cochrane风险偏差工具进行评估.
- 用Stata 17.0进行了元分析,使用相对风险 (RR) 和标准化平均差异 (SMD) 以95%的置信区间 (CI). 进行了敏感性和异质性分析,以确保结果的稳定性和探索可变性.
主要成果:
- 结合性胆固醇治疗在患者的整体评估 (SMD = 1.24,P = 0.05) 和降低硬度 (SMD = -0.81,P = 0.01) 中显著改善.
- 没有观察到随着联合胆固醇治疗不良事件的显著增加 (RR = 0.79,P = 0.36).
- 然而,在视觉模拟得分 (VAS),西部安大略省和麦克马斯特大学关节炎指数 (WOMAC) 疼痛或功能,WOMAC总得分,医生的全球评估或修改后的临床健康评估问卷 (ModHAD) 中没有发现显著改善.
结论:
- 结合性胆固醇疗法在改善关节炎管理的某些方面表现有前途,特别是患者报告的整体评估和性.
- 组合治疗似乎是安全的,与传统治疗相比,不良事件的发生率没有增加.
- 可能需要进一步的研究来澄清它对关节炎患者其他关键疼痛和功能指数的影响.
相关概念视频
01:27Combined Effects of Drugs: Synergism
3.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.7K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
01:29Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K